About Shire Shire is the leading global biotechnology company focused on serving people with rare diseases and other highly specialized conditions. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal/Internal Medicine/Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest. With the recent acquisition of Baxalta, Shire now has a strong position in the field of hemophilia. Based on this heritage, Shire is committed to expand its portfolio of innovative therapies.
Shire aims to develop a deep understanding of the patient journey to deliver transformative and personalized therapies to improve the lives of patients with hemophilia and other bleeding conditions.
Because patients are at the center of everything we do, our company works with public and private partners in communities around the world to expand access to treatments and elevate the standards of care.
At Shire, we believe in a world with endless possibilities for patients where they can dream big and live life to the fullest.

BEBS/MG1/16-0009 – Date of creation/review: 10/2016

© Copyright 2017 - Belgian Society on Thrombosis and Haemostasis - All rights reserved.